Event Info
One year on – What’s new and what have we achieved? The New Zealand asthma landscape and the impact of the ARFNZ Asthma Guidelines
- Date: 27/10/2021Time: 06:30 PM (GMT+13:00) Auckland, Wellington
Outlook
Google
Yahoo
Apple
Prof Richard Beasley
SpeakerCNZM, DSC(OTAGO), DM(SOUTHAMPTON), MBCHB, FRCP(LONDON), FRACP, FAAAAI, FFOM(HON), FAPSR(NEW ZEALAND), FERS, FRSNZ:
Professor Richard Beasley is a physician at Wellington Regional Hospital, Director of the Medical Research Institute of New Zealand, and Professor of Medicine at Victoria University of Wellington. He is an Adjunct Professor at the University of Otago and Visiting Professor, University of Southampton, United Kingdom. He is the Chair of the Asthma and Respiratory Foundation NZ Adolescent and Adult Guidelines Working Group, and a member of the ARFNZ Scientific Advisory Board, and was previously the deputy chair of the health research council of NZ. His research interests in respiratory medicine are primarily in the fields of epidemiology and clinical management. He has over 600 publications, and a Scopus H-index of 77.
This webcast has been initiated, organised and funded by AstraZeneca. The content is intended for registered HealthCare Professionals for educational purposes. Attendance at AstraZeneca educational meetings is by invitation only and limited to registered healthcare professionals. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support.
ADVERSE EVENT COLLECTION STATEMENT: AstraZeneca continually monitor the safety profile of their products. To support this ongoing process, and to adhere with local and global regulatory obligations, we must collect all reports of potential Adverse Events (AE), special situations, and product quality complaints, in relation to a patient potentially administered an AstraZeneca product. If we identify a potential report during our communications with you, this will be shared with our medical (pharmacovigilance) team. The information may be disclosed to local and overseas regulatory authorities or other third parties (such as those providing AE case processing activities, or license partners), for the purposes of meeting pharmacovigilance requirements. If you provide your contact details to us, you consent to us using those details to contact you for further information on the AE reports.
PRIVACY STATEMENT: Your personal information (“Information”) will be collected and used by AstraZeneca Pty Ltd (“AstraZeneca”) for the purpose of administration of the webcast, for follow-up purposes and for any other purpose described in AstraZeneca’s Privacy Policy (see below for link). AstraZeneca may disclose your Information to third parties such as our related entities or service providers (including IT support/ service providers), some of which may be located overseas including in the US, European Union and Asia Pacific. Please refer to our Privacy Policy for more information about how your Information is handled and how you may seek to access or correct your Information. If you have any queries about how we handle your personal information, please write to: Privacy Officer, AstraZeneca, PO Box 131, North Ryde, NSW, 1670, Australia or email to: privacy.au@astrazeneca.com. AstraZeneca Limited, PO Box 87453, Meadowbank, Auckland 1742. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone (09) 306 5650 or via
https://contactazmedical.astrazeneca.com Or email Medical Information enquiries to
medinfo.nz@astrazeneca.com.
NZ-1493, E-011973, October 2021.
